



A single injection. A singular treatment.

MONOVISC[™] is a unique achievement for treating osteoarthritis (OA). It's the only single-injection viscosupplement approved for relief of joint pain in *all* synovial joints. Created by the makers of ORTHOVISC[®], MONOVISC is specially formulated for a single-injection regimen, giving you enhanced durability in a safe, easy-to-use, single injection.

SINGLE INJECTION

Just one injection of MONOVISC is required to treat the symptoms of OA. Other viscosupplements may require up to five injections for the same treatment. The single injection regimen:

- Decreases office visits
- Lowers cost and inconvenience to the patient
- Reduces the risk or difficulty associated with multiple injections

THE MONOVISC DIFFERENCE

MONOVISC is specially formulated for a single-injection treatment. Light cross-linking:

- Stabilizes the hyaluronic acid (HA) polymers for durability
- Retains all of the natural benefits of HA

THE SINGULAR TREATMENT

MONOVISC is designed to replace or supplement synovial fluid.

- MONOVISC provides as much HA in a single injection as three injections of ORTHOVISC
- High molecular weight HA provides excellent physical properties
- Ergonomic syringe delivers safe, effective, easy injectability through 18-21 gauge needle

SAFE, NATURAL SOURCE

MONOVISC is made from highly purified, non-animal, natural hyaluronan.



ABOUT MONOVISC

Description	MONOVISC is a sterile, non-pyrogenic, sodium hyaluronate solution, lightly cross-linked with a proprietary chemical cross-linker.
	 Contains lightly cross-linked sodium hyaluronate (NaHA) dissolved in phosphate-buffered saline at physiological osmolality Manufactured from ultra-pure, high molecular weight sodium hyaluronate produced by bacterial fermentation
Application	MONOVISC Cross-Linked Sodium Hyaluronate Injection is a single, intra-articular injection of cross-linked sodium hyaluronate designed to treat the symptoms of osteoarthritis.
Indication	MONOVISC is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints.
	 Well suited for treatment of the symptoms of human joint dysfunctions such as osteoarthritis The actions of MONOVISC are lubrication and mechanical support
Directions for use	The required amount of MONOVISC is injected through a sterile, disposable hypodermic needle of suitable gauge into the selected joint space.
Adverse reactions	Hyaluronic acid is a natural component of the tissues of the body. MONOVISC is thoroughly tested to determine that each batch conforms to the product quality attributes. Since sodium hyaluronate molecules are non-inflammatory, any phlogistic response is considered to be caused by the invasive procedure. Mild to moderate episodes of transient swelling and discomfort have occasionally been observed following intra-articular injection of sodium hyaluronate preparations. General risks associated with the procedure of injecting substances into joints may include infections and bleeding.
How supplied	MONOVISC is a sterile viscoelastic preparation supplied in a disposable glass syringe delivering 4.0 mL. Each syringe contains lightly cross-linked sodium hyaluronate dissolved in phosphate-buffered saline.
Storage	Store at 2°C to 25°C.

Refer to the Instructions for Use for complete product information.



MONOVISC

Manufactured by Anika Therapeutics, Woburn, MA. MONOVISC is a trademark, and ORTHOVISC is a registered trademark, of Anika Therapeutics, Inc. 690-006/A